An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease

Xiaoxue Fan; Xinyu Ye; Jiangrui Xu; Tianjiao Mao; Ruotong Zhang; Xinyuan Zhou; Christina C. K. Au Yeung; Chang Li; Raymond Chuen-Chung Chang; Haisong Lin; Ho Cheung Shum

doi:10.1002/advs.202509376

An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease

Xiaoxue Fan, Xinyu Ye, Jiangrui Xu, Tianjiao Mao, Ruotong Zhang, Xinyuan Zhou, Christina C. K. Au Yeung, Chang Li, Raymond Chuen-Chung Chang^*, Haisong Lin^*, Ho Cheung Shum^*

^*Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

1 Citation (Scopus)

3 Downloads (CityUHK Scholars)

Abstract

The anticipated rise in the prevalence of Alzheimer's disease (AD) under global demographic shifts necessitates the development of universally accessible screening and diagnostic tools, of which blood tests hold the promise. However, the widespread adoption of blood tests remains impeded by the lack of analytically validated biomarkers and accessible decentralized platforms. Here, the study presents a portable and automated micro-immunobeads-based electromagnetic operation system, termed MEMOs, targeting potential AD blood biomarker exosome-bound A beta 42 (Exo-A beta 42), for automated blood testing of AD. MEMOs integrates a microfluidic exosome-detection biological chip (mu-Exo Biochip) embedded with a magnetic field-responsive assay for detecting Exo-A beta 42 and a microbead operation electromagnetic chip (mu-Bead EMchip) for programmable and addressable actuation, collectively delivering a high level of accurate and automated AD testing. In both animal and clinical samples, the levels of Exo-A beta 42 measured using MEMOs have shown significant correlations with various progressive stages of AD. With the features of cost-effective manufacturing, minimized hands-on time, and an easy operation workflow, MEMOs offers an accessible pathway toward diagnosing and monitoring the progression of AD in decentralized practice.

© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH

Original language	English
Article number	e09376
Journal	Advanced Science
Volume	12
Issue number	41
Online published	18 Aug 2025
DOIs	https://doi.org/10.1002/advs.202509376
Publication status	Published - 6 Nov 2025

Funding

The authors would like to thank Mr. Haoran Pang of Westlake University for the support during the revision process. The authors thank Professor Billy Kwok-Chong Chow and Mr. Zhengyi Tao at School of Biological Sciences, The University of Hong Kong, for helping with western blotting experiments. H.L. acknowledges support from the NSFC Young Scientists Fund (Hong Kong) (No. 32201181), General Research Fund (No. 17208623). H.C.S. acknowledges support from the General Research Fund (Nos. 17306221, and 17317322) and Collaborative Research Fund (C7165-20GF) from the Research Grants Council (RGC) of Hong Kong. H.C.S. was also funded in part by the RGC Senior Research Fellow (SRFS2425-7S04) by RGC and the Health@InnoHK program of the Innovation and Technology Commission of the Hong Kong SAR Government. R.C.C.C is partially supported by Bingei and L & T Charitable Foundation Professorship in Dementia Research.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 9 Industry, Innovation, and Infrastructure

Research Keywords

automation
diagnosis
electromagnetic
microfluidics
point-of-care

Publisher's Copyright Statement

This full text is made available under CC-BY 4.0. https://creativecommons.org/licenses/by/4.0/

RGC Funding Information

RGC-funded

Access Output

10.1002/advs.202509376

355382355.pdfFinal Published version, 4.84 MBLicence: CC BY

Other Access Options

Check CityUHK Library

Permanent Link

Right click to copy link

Cite this

@article{acbc0efe977b4958bd05fe5b1c83cec4,

title = "An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease",

abstract = "The anticipated rise in the prevalence of Alzheimer's disease (AD) under global demographic shifts necessitates the development of universally accessible screening and diagnostic tools, of which blood tests hold the promise. However, the widespread adoption of blood tests remains impeded by the lack of analytically validated biomarkers and accessible decentralized platforms. Here, the study presents a portable and automated micro-immunobeads-based electromagnetic operation system, termed MEMOs, targeting potential AD blood biomarker exosome-bound A beta 42 (Exo-A beta 42), for automated blood testing of AD. MEMOs integrates a microfluidic exosome-detection biological chip (mu-Exo Biochip) embedded with a magnetic field-responsive assay for detecting Exo-A beta 42 and a microbead operation electromagnetic chip (mu-Bead EMchip) for programmable and addressable actuation, collectively delivering a high level of accurate and automated AD testing. In both animal and clinical samples, the levels of Exo-A beta 42 measured using MEMOs have shown significant correlations with various progressive stages of AD. With the features of cost-effective manufacturing, minimized hands-on time, and an easy operation workflow, MEMOs offers an accessible pathway toward diagnosing and monitoring the progression of AD in decentralized practice.{\textcopyright} 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH",

keywords = "automation, diagnosis, electromagnetic, microfluidics, point-of-care",

author = "Xiaoxue Fan and Xinyu Ye and Jiangrui Xu and Tianjiao Mao and Ruotong Zhang and Xinyuan Zhou and {Au Yeung}, {Christina C. K.} and Chang Li and Chang, {Raymond Chuen-Chung} and Haisong Lin and Shum, {Ho Cheung}",

year = "2025",

month = nov,

day = "6",

doi = "10.1002/advs.202509376",

language = "English",

volume = "12",

journal = "Advanced Science",

issn = "2198-3844",

publisher = "Wiley-VCH Verlag GmbH",

number = "41",

}

TY - JOUR

T1 - An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease

AU - Fan, Xiaoxue

AU - Ye, Xinyu

AU - Xu, Jiangrui

AU - Mao, Tianjiao

AU - Zhang, Ruotong

AU - Zhou, Xinyuan

AU - Au Yeung, Christina C. K.

AU - Li, Chang

AU - Chang, Raymond Chuen-Chung

AU - Lin, Haisong

AU - Shum, Ho Cheung

PY - 2025/11/6

Y1 - 2025/11/6

N2 - The anticipated rise in the prevalence of Alzheimer's disease (AD) under global demographic shifts necessitates the development of universally accessible screening and diagnostic tools, of which blood tests hold the promise. However, the widespread adoption of blood tests remains impeded by the lack of analytically validated biomarkers and accessible decentralized platforms. Here, the study presents a portable and automated micro-immunobeads-based electromagnetic operation system, termed MEMOs, targeting potential AD blood biomarker exosome-bound A beta 42 (Exo-A beta 42), for automated blood testing of AD. MEMOs integrates a microfluidic exosome-detection biological chip (mu-Exo Biochip) embedded with a magnetic field-responsive assay for detecting Exo-A beta 42 and a microbead operation electromagnetic chip (mu-Bead EMchip) for programmable and addressable actuation, collectively delivering a high level of accurate and automated AD testing. In both animal and clinical samples, the levels of Exo-A beta 42 measured using MEMOs have shown significant correlations with various progressive stages of AD. With the features of cost-effective manufacturing, minimized hands-on time, and an easy operation workflow, MEMOs offers an accessible pathway toward diagnosing and monitoring the progression of AD in decentralized practice.© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH

AB - The anticipated rise in the prevalence of Alzheimer's disease (AD) under global demographic shifts necessitates the development of universally accessible screening and diagnostic tools, of which blood tests hold the promise. However, the widespread adoption of blood tests remains impeded by the lack of analytically validated biomarkers and accessible decentralized platforms. Here, the study presents a portable and automated micro-immunobeads-based electromagnetic operation system, termed MEMOs, targeting potential AD blood biomarker exosome-bound A beta 42 (Exo-A beta 42), for automated blood testing of AD. MEMOs integrates a microfluidic exosome-detection biological chip (mu-Exo Biochip) embedded with a magnetic field-responsive assay for detecting Exo-A beta 42 and a microbead operation electromagnetic chip (mu-Bead EMchip) for programmable and addressable actuation, collectively delivering a high level of accurate and automated AD testing. In both animal and clinical samples, the levels of Exo-A beta 42 measured using MEMOs have shown significant correlations with various progressive stages of AD. With the features of cost-effective manufacturing, minimized hands-on time, and an easy operation workflow, MEMOs offers an accessible pathway toward diagnosing and monitoring the progression of AD in decentralized practice.© 2025 The Author(s). Advanced Science published by Wiley-VCH GmbH

KW - automation

KW - diagnosis

KW - electromagnetic

KW - microfluidics

KW - point-of-care

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001551154900001

U2 - 10.1002/advs.202509376

DO - 10.1002/advs.202509376

M3 - RGC 21 - Publication in refereed journal

C2 - 40823739

SN - 2198-3844

VL - 12

JO - Advanced Science

JF - Advanced Science

IS - 41

M1 - e09376

ER -

An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease

Abstract

Funding

UN SDGs

Research Keywords

Publisher's Copyright Statement

RGC Funding Information

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

SRFS: Deciphering Sequence-Dependent Molecular Interactions in Oligonucleotide-Based Coacervates: A Paradigm Shift in Biomaterial Design and Biomedical Engineering

GRF: Synergistic Control and Assembly of Biomolecular Condensates and Networks by Aqueous Liquid-liquid Phase Separation and Liquid-solid Phase Separation (AqLL-LS PS2)

GRF: Associative Phase Separation-induced Precision Assembly (APSPA) in Aqueous Droplets

Cite this

An Automated Micro-Immunobeads-Based Electromagnetic Operation System (MEMOs) for Blood Testing of Alzheimer's Disease

Abstract

Funding

UN SDGs

Research Keywords

Publisher's Copyright Statement

RGC Funding Information

Access Output

Other Access Options

Permanent Link

Other Files and Links

Fingerprint

Projects

SRFS: Deciphering Sequence-Dependent Molecular Interactions in Oligonucleotide-Based Coacervates: A Paradigm Shift in Biomaterial Design and Biomedical Engineering

GRF: Synergistic Control and Assembly of Biomolecular Condensates and Networks by Aqueous Liquid-liquid Phase Separation and Liquid-solid Phase Separation (AqLL-LS PS2)

GRF: Associative Phase Separation-induced Precision Assembly (APSPA) in Aqueous Droplets

Cite this